Study on the effect and safety on the 'Dexamethasone–mannitol–hyperbaric oxygen' combination therapy for patients with delayed neurological sequelae after acute carbon monoxide poisoning

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029345

Enrollment

Unknown

Registered

2020-01-25

Start date

2020-01-31

Completion date

Unknown

Last updated

2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

delayed neurological sequelae after acute carbon monoxide poisoning

Interventions

control groups:HBO2

experimental group 1:10 mg/day dexamethasone and 100 ml/12 h mannitol and HBO2

experimental group 2:10 mg/day dexamethasone and HBO2

Eligibility

Sex/Gender

Male

Age

42 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1) patients with a clear history of CO poisoning; 2) patients with a history of coma; 3) patients who met the criteria of DNS; 4) patients with Mini-Mental State Examination (MMSE) score of not more than 24; 5) and patients who provided written informed consent.

Exclusion criteria

Exclusion criteria: 1) patients who were allergic to dexamethasone; 2) patients with poor blood glucose control; 3) patients with renal insufficiency; 4) patients with original intellectual disability; 5) patients who were pregnant; 6) patients older than 80 years; 7) patients with bullae and pneumothorax; 8) and patients with contraindications to HBO2.

Design outcomes

Primary

Measure	Time frame
MMSE score;	—

Countries

China

Contacts

Public ContactDazhi Guo

The Sixth Medical Center, PLA General Hospital

guodazhigod1983@163.com+86 18600317342

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026